PARIS — Enodia Therapeutics has appointed Yvonne McGrath, Ph.D., as Chief Scientific Officer, adding a veteran drug development executive to help advance its targeted protein degradation platform.
Dr. McGrath brings more than 25 years of experience in biopharma and life sciences. She will help guide the company’s strategy as it develops small-molecule therapies designed to degrade disease-causing proteins at the point of synthesis.
“Yvonne joins Enodia to help translate our scientific vision into meaningful clinical progress,” said Yves Ribeill, Chief Executive Officer of Enodia Therapeutics. “She brings a wealth of translational experience across the industry, spanning multiple drug modalities and indications. With firsthand experience advancing novel drug candidates into the clinic, her insights will be instrumental in sharpening our translational strategy and accelerating our timelines, as we progress our small molecules designed to halt pathological proteins at the source.”
Before joining Enodia, Dr. McGrath served as Chief Scientific Officer at iTeos Therapeutics, where she led discovery and translational efforts in immuno-oncology. She previously held the same role at Complix N.V., overseeing research and development strategy for protein therapeutics in oncology. Earlier in her career, she held multiple leadership roles at Immunocore, helping advance a therapy later approved for the treatment of uveal melanoma.
“Enodia’s differentiated platform integrates multiple state-of-the-art approaches, including machine learning and proteomics, to engineer drug candidates for selective Sec61 modulation,” said Dr. McGrath. “Joining at this critical juncture in the company’s growth, I’m excited by what the team is building and look forward to working with Yves Ribeill and the rest of the team at Enodia to accelerate the development of therapies for patients with limited treatment options.”
Enodia’s approach focuses on targeting proteins as they are being produced, aiming to stop disease-driving proteins before they fully form. The company said this strategy could open new possibilities for treating conditions that have been difficult to address using traditional drug development methods.
The company is supported by a Scientific Advisory Board of academic and industry experts who help guide its research and development strategy as it advances its pipeline.
